AR074107A1 - Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina - Google Patents
Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarinaInfo
- Publication number
- AR074107A1 AR074107A1 ARP090104347A ARP090104347A AR074107A1 AR 074107 A1 AR074107 A1 AR 074107A1 AR P090104347 A ARP090104347 A AR P090104347A AR P090104347 A ARP090104347 A AR P090104347A AR 074107 A1 AR074107 A1 AR 074107A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- years old
- dabigatran
- history
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un método para prevenir apoplejías en un paciente que sufre de fibrilacion auricular, donde el paciente no tiene factores de riesgo de episodios de sangrado graves, el método comprende administrar al paciente 150 mg dos veces al día de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo. Reivindicacion 7: El método de acuerdo con la reivindicacion 6, caracterizado porque el paciente no ha sido sometido a cirugía en un plazo de 90 días. Reivindicacion 14: El método de acuerdo con la reivindicacion 13, caracterizado porque el factor de riesgo de apoplejía, trombosis, o embolia se selecciona del grupo que consiste en; (a) tener una edad de al menos 75 anos; (b) tener un historial de apoplejías; (c) tener un historial de un ataque isquémico transitorio; (d) tener un historial de un episodio tromboembolico; (e) tener una disfuncion ventricular izquierda; (f) tener una edad de al menos 65 anos y tener presion sanguínea elevada; (g) tener una edad de al menos 65 anos y tener diabetes; (h) tener una edad de al menos 65 anos y tener una enfermedad arterial coronaria; y (i) tener una edad de al menos 65 anos y tener una enfermedad arterial periférica. Reivindicacion 16: El método de acuerdo con la reivindicacion 13, caracterizado porque el paciente tiene fibrilacion auricular. Reivindicacion 22: Un método para prevenir o tratar la trombosis en un paciente necesitado de dicho tratamiento, caracterizado porque el método que comprende administrar 150 mg dos veces al día de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo, donde para el paciente no es adecuada la terapia convencional con warfarina. Reivindicacion 24: El método de acuerdo con la reivindicacion 5, caracterizado porque el paciente tiene una depuracion de creatina mayor que 30 mL/min. Reivindicacion 25: El método de acuerdo con la reivindicacion 5, caracterizado porque además comprende discontinuar la administracion de dabigatrán si el paciente tiene una depuracion de creatina de 30 mL/min., o menos. Reivindicacion 34: Un método para prevenir apoplejías en un paciente con fibrilacion auricular, caracterizado porque el método comprende administrar 150 mg dos veces al día de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo, al paciente y modificar la administracion segun sea necesario para mantener los niveles de dabigatrán en plasma en el paciente entre aproximadamente 20 ng/mL y aproximadamente 180 ng/mL, donde el paciente está en un riesgo reducido de un episodio de sangrado grave en comparacion con la terapia convencional con warfarina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11341308P | 2008-11-11 | 2008-11-11 | |
US23755909P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074107A1 true AR074107A1 (es) | 2010-12-22 |
Family
ID=41463075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104347A AR074107A1 (es) | 2008-11-11 | 2009-11-10 | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina |
Country Status (21)
Country | Link |
---|---|
US (3) | US20110269799A1 (es) |
EP (1) | EP2355823A1 (es) |
JP (1) | JP2013510073A (es) |
KR (1) | KR20110082564A (es) |
CN (2) | CN103463083A (es) |
AR (1) | AR074107A1 (es) |
AU (1) | AU2009315730A1 (es) |
BR (1) | BRPI0921354A2 (es) |
CA (1) | CA2738884A1 (es) |
CL (1) | CL2011000806A1 (es) |
CO (1) | CO6382133A2 (es) |
EA (1) | EA201100755A1 (es) |
EC (1) | ECSP11011029A (es) |
IL (1) | IL211853A0 (es) |
MA (1) | MA32785B1 (es) |
MX (1) | MX2011004796A (es) |
NZ (1) | NZ592615A (es) |
PE (1) | PE20110432A1 (es) |
TN (1) | TN2011000227A1 (es) |
TW (1) | TW201031651A (es) |
WO (1) | WO2010055022A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103356614A (zh) | 2008-11-11 | 2013-10-23 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良安全性的方法 |
LT2550966T (lt) * | 2011-07-25 | 2017-01-25 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
CN108254216B (zh) * | 2018-03-15 | 2021-04-27 | 攀钢集团西昌钢钒有限公司 | 一种高炉槽的矿料取样方法、装置及可读存储介质 |
US20220175748A1 (en) * | 2019-03-06 | 2022-06-09 | University Of Rochester | Anticoagulant compositions and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
WO2008009638A2 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
-
2009
- 2009-11-10 BR BRPI0921354A patent/BRPI0921354A2/pt not_active IP Right Cessation
- 2009-11-10 EA EA201100755A patent/EA201100755A1/ru unknown
- 2009-11-10 CN CN2013102966233A patent/CN103463083A/zh active Pending
- 2009-11-10 US US13/128,460 patent/US20110269799A1/en not_active Abandoned
- 2009-11-10 TW TW098138140A patent/TW201031651A/zh unknown
- 2009-11-10 CA CA2738884A patent/CA2738884A1/en not_active Abandoned
- 2009-11-10 MX MX2011004796A patent/MX2011004796A/es not_active Application Discontinuation
- 2009-11-10 PE PE2011001003A patent/PE20110432A1/es not_active Application Discontinuation
- 2009-11-10 EP EP09755873A patent/EP2355823A1/en not_active Withdrawn
- 2009-11-10 AR ARP090104347A patent/AR074107A1/es unknown
- 2009-11-10 NZ NZ592615A patent/NZ592615A/xx not_active IP Right Cessation
- 2009-11-10 JP JP2011535125A patent/JP2013510073A/ja active Pending
- 2009-11-10 AU AU2009315730A patent/AU2009315730A1/en not_active Abandoned
- 2009-11-10 WO PCT/EP2009/064874 patent/WO2010055022A1/en active Application Filing
- 2009-11-10 CN CN2009801448169A patent/CN102209546A/zh active Pending
- 2009-11-10 KR KR1020117010632A patent/KR20110082564A/ko not_active Application Discontinuation
-
2010
- 2010-06-17 US US12/817,369 patent/US20100322870A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211853A patent/IL211853A0/en unknown
- 2011-04-12 CL CL2011000806A patent/CL2011000806A1/es unknown
- 2011-05-04 EC EC2011011029A patent/ECSP11011029A/es unknown
- 2011-05-10 TN TN2011000227A patent/TN2011000227A1/fr unknown
- 2011-05-11 CO CO11058058A patent/CO6382133A2/es not_active Application Discontinuation
- 2011-05-11 MA MA33833A patent/MA32785B1/fr unknown
-
2012
- 2012-07-06 US US13/543,080 patent/US20120277269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103463083A (zh) | 2013-12-25 |
NZ592615A (en) | 2013-06-28 |
CN102209546A (zh) | 2011-10-05 |
AU2009315730A1 (en) | 2010-05-20 |
US20110269799A1 (en) | 2011-11-03 |
MX2011004796A (es) | 2011-05-30 |
BRPI0921354A2 (pt) | 2019-09-24 |
CL2011000806A1 (es) | 2011-11-11 |
TN2011000227A1 (en) | 2012-12-17 |
KR20110082564A (ko) | 2011-07-19 |
PE20110432A1 (es) | 2011-07-16 |
JP2013510073A (ja) | 2013-03-21 |
US20120277269A1 (en) | 2012-11-01 |
WO2010055022A1 (en) | 2010-05-20 |
CO6382133A2 (es) | 2012-02-15 |
CA2738884A1 (en) | 2010-05-20 |
IL211853A0 (en) | 2011-06-30 |
EA201100755A1 (ru) | 2011-12-30 |
EP2355823A1 (en) | 2011-08-17 |
MA32785B1 (fr) | 2011-11-01 |
TW201031651A (en) | 2010-09-01 |
ECSP11011029A (es) | 2011-06-30 |
US20100322870A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074107A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
AR074108A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
JP2017505761A5 (es) | ||
AR119158A1 (es) | Tratamientos de angioedema hereditario | |
WO2008073392A3 (en) | Compositions and methods for cardiac tissue protection and regeneration | |
AR081439A1 (es) | Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata | |
Yui et al. | Comparative effects of verapamil, nicardipine, and nitroglycerin on myocardial ischemia/reperfusion injury | |
RU2519228C1 (ru) | Способ предупреждения ишемии головного мозга при реконструктивных операциях на прецеребральных сосудах | |
Bunch et al. | Revisiting rate versus rhythm control in atrial fibrillation—timing matters | |
AR105752A1 (es) | Métodos para el tratamiento de enfermedades cardiovasculares | |
AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
Selvaraj et al. | Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery | |
Hiatt et al. | Prolongation of survival after circumflex artery ligation by treatment with massive doses of insulin | |
RU2004136583A (ru) | Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов | |
Koga et al. | The protective effects of CP‐060S on ischaemia‐and reperfusion‐induced arrhythmias in anaesthetized rats | |
AR061635A1 (es) | Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos | |
Elgariah et al. | Effect of terminal warm reperfusion (hot shot) and remote ischemic preconditioning, either separately or combined, on myocardial recovery in adult cardiac surgery | |
RU2006142622A (ru) | Способ лечения острого инфаркта миокарда | |
RU2007135967A (ru) | Регенерирующее противовоспалительное средство и способы лечения с помощью этого средства | |
AR122400A1 (es) | Uso de agentes para el tratamiento de afecciones respiratorias | |
AR125886A1 (es) | Composición farmacéutica para prevenir o tratar la fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |